APGE (Apogee Therapeutics) Accounts Payable & Accrued Expense : $23.76 Mil (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Apogee Therapeutics Accounts Payable & Accrued Expense?

Apogee Therapeutics's quarterly accounts payable & accrued expense increased from Sep. 2024 ($22.83 Mil) to Dec. 2024 ($23.43 Mil) and increased from Dec. 2024 ($23.43 Mil) to Mar. 2025 ($23.76 Mil).

Apogee Therapeutics's annual accounts payable & accrued expense increased from Dec. 2022 ($9.47 Mil) to Dec. 2023 ($19.29 Mil) and increased from Dec. 2023 ($19.29 Mil) to Dec. 2024 ($23.43 Mil).

Apogee Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Apogee Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apogee Therapeutics Accounts Payable & Accrued Expense Chart

Apogee Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

9.47

19.29

23.43

Apogee Therapeutics Quarterly Data
	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial							18.12	18.88	22.83	23.43	23.76

Apogee Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Apogee Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apogee Therapeutics Inc (NAS:APGE) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

221 Crescent Street, Building 17, Suite 102b, Waltham, MA, USA, 02453

Website

https://www.apogeetherapeutics.com

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Executives

Carl Dambkowski	officer: Chief Medical Officer	221 CRESCENT ST., BUILDING 17, SUITE 102B, WALTHAM MA 02453
Michael Thomas Henderson	director, officer: Chief Executive Officer	421 KIPLING STREET, PALO ALTO CA 94301
Mark C. Mckenna	director	400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807
Jane Henderson	officer: Chief Financial Officer	C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Nimish P Shah	director	7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018
Peter Evan Harwin	director	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jones William A Jr	director	NITROMED, INC., 125 SPRING STREET, LEXINGTON MA 02421
Fairmount Funds Management Llc	director	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Fairmount Healthcare Fund L.p.	director	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Healthcare Fund Ii L.p.	director	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Tomas Kiselak	director	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jennifer A. Fox	director	C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036
Andrew Gottesdiener	director	3340 HILLVIEW AVE, PALO ALTO CA 94304
Fairmount Healthcare Co-invest Ii L.p.	director	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428